Endocrine Testing Market Report 2026

Endocrine Testing Market Overview

• Endocrine Testing market size has reached to $2.79 billion in 2025 • Expected to grow to $4.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.9% • Growth Driver: Impact of Diabetes Prevalence on Endocrine Testing Market Growth • Market Trend: Point-Of-Care NT-Probnp Test For Cardiovascular Risk Screening In Diabetic Patients • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Endocrine Testing Market?

Endocrine testing refers to the diagnostic process of evaluating hormone levels in the body, typically through blood, urine, or saliva tests, to assess the function of the endocrine system. These tests are crucial for diagnosing various endocrine disorders, including diabetes, thyroid disorders, adrenal insufficiency, and pituitary gland disorders. Endocrine testing helps healthcare providers determine the appropriate treatment and management plans for patients with these conditions. The main types of endocrine testing include estradiol (E2) test, follicle stimulating hormone (FSH) test, human chorionic gonadotropin (HCG) hormone test, luteinizing hormone (LH) test, dehydroepiandrosterone sulfate (DHEAS) test, progesterone test, testosterone test, thyroid stimulating hormone (TSH) test, prolactin test, and others. The Estradiol (E2) Test refers to a blood test that measures the levels of estradiol in the body. They are based on various technologies including tandem mass spectrometry, immunoassay, monoclonal and polyclonal antibody technologies, sensor technology, clinical chemistry, and others used by hospitals, clinical laboratories, diagnostic centers, and others.

What Is The Endocrine Testing Market Growth Forecast?

The endocrine testing market size is expected to see strong growth in the next few years. It will grow to $4.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to preventive healthcare focus, personalized treatment planning, automation in hormone testing, expansion of diagnostic centers, endocrine disease screening programs. Major trends in the forecast period include growing prevalence of hormonal disorders, increased adoption of comprehensive hormone panels, expansion of preventive endocrine screening, rising demand for accurate diagnostic results, integration of advanced diagnostic technologies.

Global Endocrine Testing Market Segmentation

1) By Test Type: Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test, Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Other Types 2) By Technology: Tandem Mass Spectrometry, Immunoassay, Monoclonal And Polyclonal Antibody Technologies, Sensor Technology, Clinical Chemistry, Other Technologies 3) By End-User: Hospitals, Clinical Laboratories, Diagnostic Centers, Other End-Users Subsegments: 1) By Estradiol (E2) Test: Serum Estradiol Test, Urinary Estradiol Test 2) By Follicle Stimulating Hormone (FSH) Test: FSH Serum Test, FSH Urine Test 3) By Human Chorionic Gonadotropin (hCG) Hormone Test: Quantitative hCG Test, Qualitative hCG Test 4) By Luteinizing Hormone (LH) Test: LH Serum Test, LH Urine Test 5) By Dehydroepiandrosterone Sulfate (DHEAS) Test: Serum DHEAS Test, Saliva DHEAS Test 6) By Progesterone Test: Serum Progesterone Test, Urinary Progesterone Test 7) By Testosterone Test: Free Testosterone Test, Total Testosterone Test 8) By Thyroid Stimulating Hormone (TSH) Test: TSH Serum Test, TSH Saliva Test 9) By Prolactin Test: Serum Prolactin Test, Plasma Prolactin Test 10) By Other Types: Cortisol Test, Insulin Test, Growth Hormone (GH) Test, Aldosterone Test

What Is The Driver Of The Endocrine Testing Market?

The rising prevalence of diabetes is expected to propel the growth of the endocrine testing market going forward. Diabetes refers to a group of diseases that result in high blood sugar (glucose) levels. The prevalence of diabetes is increasing due to factors such as unhealthy diets, sedentary lifestyles, genetic predisposition, and an aging population. Endocrine testing, including hemoglobin A1c, fasting plasma glucose, and C-peptide tests, is used in diabetes to diagnose the condition, monitor glucose levels, and assess insulin production and sensitivity. For instance, in June 2024, according to the National Health Service (NHS), UK-based government department, among individuals under 40, rising from 173,166 in 2022 to 216,440 in 2023. This significant growth highlights a concerning trend in this age group. The data reflects a rapid escalation in diabetes prevalence among younger populations. Therefore, the rising prevalence of diabetes is driving the endocrine testing industry.

Key Players In The Global Endocrine Testing Market

Major companies operating in the endocrine testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Roche Holding, Siemens Healthineers, Quest Diagnostics, Agilent Technologies Inc., PerkinElmer Inc., BioMérieux SA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., SD Biosensor Inc., Qiagen N.V., Ortho Clinical Diagnostics, Kronus Inc., Randox Laboratories Ltd., Fujirebio Diagnostics Inc., Inova Diagnostics Inc., Sekisui Diagnostics LLC, Mercodia AB, ZEUS Scientific Inc., IBL International, Monobind Inc., Agilus Diagnostics, Tosoh Bioscience Inc., DiaSorin S.p.A.

Global Endocrine Testing Market Trends and Insights

Major companies operating in the endocrine testing market are developing point-of-care testing solutions to enhance the accessibility and efficiency of diagnosing endocrine disorders. Point-of-care testing allows for quick results, which can aid in the rapid diagnosis and management of heart failure in patients presenting with symptoms such as shortness of breath and fatigue. For instance, in April 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched a point-of-care NT-proBNP test in India, specifically designed for screening diabetes patients at risk of cardiovascular diseases, such as heart failure (HF). It facilitates early detection and intervention, enabling clinicians to identify high-risk T2D patients and initiate timely treatment discussions. The test facilitates early detection and intervention, allowing the clinicians to identify high-risk T2D patients and initiate timely treatment discussions, ultimately fostering improved outcomes and patient well-being.

What Are Latest Mergers And Acquisitions In The Endocrine Testing Market?

In February 2025, Hims And Hers Health Inc., a US–based healthcare technology company, acquired Trybe, Inc. for an undisclosed amount. With this acquisition, Hims & Hers aimed to expand its at-home diagnostic testing capabilities, enhance its service offerings across hormone and wellness testing, and strengthen its subscription-based customer experience. Trybe, Inc. is a US–based healthcare technology company that specializes in providing at-home laboratory testing services, including whole-body and hormone-related tests, to support personalized health and wellness insights.

Regional Outlook

North America was the largest region in the endocrine testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Endocrine Testing Market?

The endocrine testing market consists of revenues earned by entities by providing services such as hormone level testing, thyroid function testing, diabetes testing, adrenal function testing, reproductive hormone testing, pituitary function testing, and bone metabolism testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The endocrine testing market also includes sales of assay kits, analyzers, point-of-care testing devices, reagents, software solutions, quality control materials, and calibrators and controls. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Endocrine Testing Market Report 2026?

The endocrine testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the endocrine testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.